Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].

Annales de pathologie - 1 Feb 2017

Duruisseaux Michaël, Lize-Dufranc Cécile, Badoual Céline, Bibeau Frédéric

Abstract excerpt

The remarkable efficacy of PD-1/PD-L1 and CTLA4 immune checkpoint inhibitors has led to numerous approvals in melanoma, non-small cell lung cancer, kidney cancer and several other cancers. Nevertheless, a response is observed in a variable proportion of patients, emphasizing the need for predictive biomarkers of efficacy of immune checkpoint inhibitors effectiveness. Several predictive biomarkers of efficacy are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CTLA-4 Antigen

Share to Drug Monitoring

Share to Lymphocytes, Tumor-Infiltrating

Share to Patient Selection

Share to Programmed Cell Death 1 Receptor

Share to Tumor Virus Infections

Source

Identifiers

PMID: 28131419
DOI: 10.1016/j.annpat.2016.12.016

Genes

CTLA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].PMID 28131419Read ↗

Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.Semantic proximity Read ↗

Biomarker for personalized immunotherapySemantic proximity Read ↗

Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.Semantic proximity Read ↗

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.Semantic proximity Read ↗

Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).Semantic proximity Read ↗

Predictive biomarkers for response to immune checkpoint inhibitionSemantic proximity Read ↗

Biomarkers of response to PD-1 pathway blockadeSemantic proximity Read ↗

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology TrialsSemantic proximity Read ↗

Biomarkers for Checkpoint InhibitionSemantic proximity Read ↗

PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.Semantic proximity Read ↗

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.Semantic proximity Read ↗

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.